CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo tested to push CML into deeper remission
Disease control OngoingThis study is testing whether adding a drug called ruxolitinib to standard CML medications helps patients achieve a deeper level of disease control. The trial involves 81 adults with chronic phase CML who still have detectable disease despite being on standard treatment. Particip…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 04, 2026 02:05 UTC
-
New drug combo aims to control blood cancer in early phase
Disease control OngoingThis study is testing whether combining two drugs, dasatinib and venetoclax, can better control early-stage chronic myeloid leukemia (CML) than one drug alone. It will involve about 155 adults newly diagnosed with this type of blood cancer. The main goal is to see if the combinat…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to help CML patients stop treatment
Disease control OngoingThis study is testing if adding an immunotherapy drug called pembrolizumab to standard CML medications can help patients achieve a deeper remission. It is for patients whose cancer is controlled but still detectable at very low levels. The goal is to see if this combination can e…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New vaccine aims to shield vulnerable cancer patients from dangerous virus
Prevention OngoingThis study is testing a vaccine designed to prevent cytomegalovirus (CMV) infection in adults with blood cancers who are receiving a half-matched stem cell transplant. CMV is a common virus that can become life-threatening when the immune system is weakened after transplant. The …
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Mar 16, 2026 15:25 UTC